secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001438533-24-000003
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Q4 net product sales $39.9M, FILSPARI PSFs total 1,452 in 2023; sNDA filing imminent
--------------------------------------------------------------------------------

- Net product sales of $39.9M in Q4 2023 ($127.5M FY); driven by FILSPARI launch ($14.7M Q4).
- Q4 2023 net loss $90.2M ($1.18/sh); cash and equivalents $566.9M at Dec 31, 2023.
- Received 459 new patient start forms for FILSPARI in Q4; total 1,452 PSFs since Feb 2023 approval.
- Expects to submit sNDA for full U.S. approval of FILSPARI in IgAN in Q1 2024; CHMP opinion on EU CMA also Q1.
- Pivotal Phase 3 HARMONY study of pegtibatinase in HCU enrolling; topline data expected in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853324000003/0001438533-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853324000003/tvtx-20240215.htm
  HTML page:      https://secwatch.observer/filing/0001438533-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer